Zuzanna Lechowska

Zuzanna Lechowska

Auto-generated profile, based on publicly available information

Zuzanna Lechowska

Gabriel Narutowicz Hospital, Kraków, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WKWiktoria Król
Wiktoria Król
KKKonrad Kulka
Konrad Kulka
DJDominika Jurczak
Dominika Jurczak
JKJulia Koronczok-Matusiak
Julia Koronczok-Matusiak
ZKZuzanna Kafara
Zuzanna Kafara
KMKatarzyna Michta
Katarzyna Michta
Treating cancers is a challenge that many scientists from around the world face every day. Thanks to the scientific advances, cancers are now divided not only by the organ they affect, but also into subtypes such as histological and molecular. Small molecules present on cancer cells have become the target of molecular drugs, making cancer treatment even more personalized for specific type. One of them is the use of trastuzumab - a targeted monoclonal antibody used in the treatment of cancers with overexpression of the HER2 protein on cell membrane. Trastuzumab inhibits the growth of cancer cells by blocking HER2 receptors. This mechanism is used in the treatment of HER2-positive breast and stomach cancer. In clinical trials, trastuzumab has been shown to have significantly higher rates of disease-free survival, absolute survival rate, median overall survival, progression-free survival and the duration of response than similar therapies without it. This makes it promising and useful in anticancer therapy in some neoplasm types. In addition, the safety profile has been checked and assessed in many respects, taking into account the side effects that this drug causes.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KMKatarzyna Michta
Katarzyna Michta
ZLZuzanna Lechowska
Zuzanna Lechowska
ZKZuzanna Kafara
Zuzanna Kafara
AKAgnieszka Kafara
Agnieszka Kafara
DJDominika Jurczak
Dominika Jurczak
RSRafał Szarek
Rafał Szarek
Background: Neurological conditions are now the leading cause of disability worldwide. Frailty syndrome, defined as a multisystemic state of physiological impairment, often predicts clinical outcomes more accurately than chronological age. Objective: This review examines the molecular pathophysiology of neuro-frailty, its prognostic significance in acute ischemic stroke, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as the integration of emerging diagnostic technologies. Methodology: A comprehensive review of English-language articles published from 2001 to 2026 in PubMed, Scopus, and Cochrane was conducted. Grey literature and animal studies were excluded from the analysis. The synthesis focused on meta-analyses and human-based research connecting artificial intelligence diagnostics, fluid biomarkers, and clinical neurology. Results: Neuro-frailty is associated with the phenomenon of inflammaging, the secretory ageing-associating phenotype (SASP), and progressive mitochondrial dysfunction. The presence of pre-existing frailty also elevates the risk of unfavorable functional recovery (mRS > 2) in acute phase of ischaemic stroke by 3.11 times. In MS, ongoing neurodegeneration accelerates biological ageing, often resulting in premature frailty. The sarcopenia-frailty axis in Parkinson’s disease affects over 35% of patients and significantly increases the risk of recurrent falls. Modern diagnostic methods now enable objective and precise quantification of this impairment. Conclusions: Frailty is a dynamic clinical condition that is possible to reverse. The transition from age-based metrics to AI-powered biological screening enables a personalized approach to care by clinicians. These targeted strategies are essential for maintaining neurological functions and reducing socio-economic consequences of ageing.

25 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DKDonata Kowalczyk
Donata Kowalczyk
DJDominika Jurczak
Dominika Jurczak
AKAgnieszka Kafara
Agnieszka Kafara
ZKZuzanna Kafara
Zuzanna Kafara
JKJulia Koronoczok-Matusiak
Julia Koronoczok-Matusiak
RKRobert Kowalczyk
Robert Kowalczyk
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in the identification and treatment of classic risk factors. Accumulating evidence suggests that psychosocial stress may play a significant role in the development and progression of CVD through biological and behavioral mechanisms. Objective: The aim of the study was to summarize the current knowledge on the relationship between psychosocial stress and cardiovascular diseases, with particular emphasis on the pathophysiological mechanisms underlying this relationship and the possibilities of stress reduction in the prevention and treatment of CVD. Methods: A narrative literature review was conducted using PubMed, Nature Reviews, and Google Scholar. Scientific publications published primarily between 2014 and 2025 were analyzed, including systematic reviews, meta-analyses, cohort studies, clinical trials, experimental studies, and epidemiological reports. Papers on the biological and psychological mechanisms linking psychosocial stress with cardiovascular diseases and interventions aimed at reducing stress were included. Results: Psychosocial stress should be viewed as a multidimensional risk factor for cardiovascular disease, potentially contributing to both its development and progression. Incorporating stress assessment and implementing effective stress reduction strategies may be a valuable complement to current CVD prevention and treatment strategies. Further research involving large patient populations is needed to determine the role of stress-reducing interventions in routine cardiac care.

4 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
JKJulia Koronczok-Matusiak
Julia Koronczok-Matusiak
DJDominika Jurczak
Dominika Jurczak
ZKZuzanna Kafara
Zuzanna Kafara
DKDonata Kowalczyk
Donata Kowalczyk
WKWiktoria Król
Wiktoria Król
KMKatarzyna Michta
Katarzyna Michta
Endoscopic examination plays a crucial role in the secondary prevention of gastric cancer. However, its effectiveness is often limited by the subjective nature of assessment and the risk of missing neoplastic lesions. The use of deep learning (DL) and machine learning (ML) models allows for a significant improvement in the quality of endoscopic diagnosis of early gastric cancer. Real-time systems increase the sensitivity of the examination and reduce skill-based differences between endoscopists. They also enable precise assessment of tumor invasion depth, which is essential for qualifying patients for minimally invasive treatment. Explainable artificial intelligence (XAI) methods and ML algorithms are gaining increasing importance as they enhance the transparency of the diagnostic process. Despite promising data, the full implementation of AI systems in endoscopy faces challenges such as susceptibility to imaging artifacts, the risk of model overfitting, and regulatory hurdles. A key issue remains the development of representative, multicenter training image databases and the conduct of prospective clinical trials, which may revolutionize standards of care. The aim of this article is to discuss the role of AI-assisted gastroscopy in the prevention of early gastric cancer, with particular emphasis on its potential in population-based screening programs. The paper presents current clinical data and analyzes the benefits and challenges associated with implementing these technologies into routine clinical practice.

29 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
KKKonrad Kulka
Konrad Kulka
WKWiktoria Król
Wiktoria Król
ZKZuzanna Kafara
Zuzanna Kafara
DKDonata Kowalczyk
Donata Kowalczyk
ZLZuzanna Lechowska
Zuzanna Lechowska
DJDominika Jurczak
Dominika Jurczak
The growing number of oncological patients worldwide pushes the need to research new possibilities in cancer treatment. Cancer cells use various mechanisms to avoid destruction. One of them is the PD-1/PD-L1 pathway which is used by neoplasm cells to inhibit immune response from T-cells. Pembrolizumab, a monoclonal antibody, is targeted against PD-1 receptors, therefore enhances anti-cancer T-cell activity by disabling PD-1/PD-L1 interaction. This study summarizes the current state of knowledge on clinical usefulness and efficiency of pembrolizumab monotherapy, therapy combined with chemotherapy and perioperative use in melanoma, non-small cell lung cancer, pleural mesothelioma, classic Hodgkin lymphoma, urothelial cancer, head and neck squamous cell carcinoma, renal cell carcinoma, high-level microsatellite instability (MSI-H) or demismatch repair deficiency (dMMR) neoplasm, esophageal cancer, triple negative breast cancer, endometrial cancer, cervical cancer, adenocarcinoma of the stomach or gastroesophageal junction and bile duct cancer. Patients who received pembrolizumab during clinical trials had longer median overall survival and progression free survival rates than patients in placebo groups. Higher expression levels of PD-L1 on tumor cells correlated with greater clinical response, however pembrolizumab therapy was also beneficial in patients with lower expression levels.

19 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZKZuzanna Kafara
Zuzanna Kafara
DJDominika Jurczak
Dominika Jurczak
JKJulia Koronczok-Matusiak
Julia Koronczok-Matusiak
AKAgnieszka Kafara
Agnieszka Kafara
KKKonrad Kulka
Konrad Kulka
RSRafał Szarek
Rafał Szarek
Research objectives: Regular physical activity is widely recognized as a key component of a healthy lifestyle. While moderate effort brings numerous benefits, engaging in extreme physical activity introduces new challenges and risks. Intense exercise, despite its undeniable health benefits, can lead to unpredictable changes in the body. This paper identifies the possible adaptive changes of the cardiovascular system and the risk of developing overtraining syndrome as a result of long-term practice of intense exercise. Methods and key findings: Two medical textbooks, thirty-eight scientific articles published between 2010 and 2024, and one article from 2005 were reviewed, with findings indicating that regular high-intensity training can lead to myocardial hypertrophy, reduced resting heart rate, and a smaller increase in heart rate in response to submaximal effort. An increased risk of arrhythmias and myocardial fibrosis has been observed in competitive athletes. Prolonged excessive exercise can result in overtraining syndrome, which may present as persistent fatigue, muscle and joint discomfort, and mood disturbances, among other symptoms. Conclusions: The paper emphasizes the need to individualize training programs and proves the validity of regular monitoring of athletes' health. It also highlights the necessity for further research into overtraining syndrome and the adaptation of the cardiovascular system to intense exercise. Particular attention was paid to the diagnostic difficulties associated with overtraining syndrome due to the subjectivity of symptoms and the limited number of clinical studies. The significance of an interdisciplinary approach in understanding the body's adaptation to overload was emphasized, considering physiological, biochemical, and psychological factors.